TrialNet Abatacept Prevention Study
Study Name: CTLA4-Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus
Principal Investigator: Desmond Schatz, M.D.
Coordinator: Roberta Cook, RN, BSN, CDE
What is the Abatacept Prevention Study?
The goal of this study is to learn if the drug Abatacept will help delay or prevent the onset of abnormal glucose levels and/ or the onset of type 1 diabetes by delaying or preventing beta cell destruction.
Who can participate?
Participants in the TrialNet Natural History Pathway to Prevention Study who meet specific criteria are eligible.
What will study participants be asked to do?
The screening visit will occur at the University of Florida and will include blood tests to determine eligibility for this study
If the results from this screening visit show that the participant is eligible, they will be offered the opportunity to enroll in the intervention part of the study
- Half the people will receive Abatacept, half will receive placebo (an inactive substance)
- You and your study team will not know if you receive Abatacept or placebo
- You will receive 14 infusions within the first year of the study.
- You will have an Oral Glucose Tolerance Test (OGTT) every 6 months
Informed Consent available upon request.